Advair (Fluticasone Propionate / Salmeterol)
fluticasone propionate and salmeterol inhalation powder / inhalation aerosol
Indications
| Indication | Approved Population | Therapy Type | Status |
|---|---|---|---|
| Asthma — maintenance treatment (Diskus) | ≥4 years | ICS/LABA combination for patients not controlled on ICS alone or warranting dual therapy | FDA Approved |
| Asthma — maintenance treatment (HFA) | ≥12 years | ICS/LABA combination | FDA Approved |
| COPD — maintenance of airflow obstruction and exacerbation reduction (Diskus 250/50 only) | Adults | Maintenance; patients with exacerbation history | FDA Approved |
Fluticasone-salmeterol is a fixed-dose combination of an inhaled corticosteroid and a long-acting beta2-agonist. In asthma, it is reserved for patients not adequately controlled on an ICS alone or whose disease severity warrants initiation of both components. GINA guidelines position ICS/LABA combinations at step 3 and above. For COPD, only the Diskus 250/50 strength is approved; higher strengths did not demonstrate additional efficacy. Advair is not for the relief of acute bronchospasm.
Exercise-induced bronchoconstriction (maintenance prevention): Regular ICS/LABA use as controller therapy reduces EIB severity; salmeterol provides additional bronchodilator duration. Evidence quality: High.
Asthma-COPD overlap (ACO): ICS/LABA combinations are a cornerstone of ACO management per GOLD/GINA joint recommendations. Evidence quality: Moderate.
Dosing
Advair Diskus (DPI) — Asthma
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Mild-to-moderate persistent asthma — inadequately controlled on low-dose ICS (≥12 y) | 100/50 mcg 1 inh BID | 100/50 – 250/50 mcg BID | 500/50 mcg BID | Choose starting strength based on current ICS dose If inadequate after 2 weeks, step up to next strength |
| Moderate persistent asthma — on medium-dose ICS (≥12 y) | 250/50 mcg 1 inh BID | 250/50 mcg BID | 500/50 mcg BID | Titrate to lowest effective strength once stable Improvement may begin within 30 min; max benefit 1 week+ |
| Severe persistent asthma — on high-dose ICS or oral steroids (≥12 y) | 500/50 mcg 1 inh BID | 500/50 mcg BID | 500/50 mcg BID | For oral steroid taper: reduce prednisone by 2.5 mg/day weekly after ≥1 week on Advair Monitor for adrenal insufficiency during taper |
| Pediatric asthma (4–11 y) | 100/50 mcg 1 inh BID | 100/50 mcg BID | 100/50 mcg BID | Only strength approved for this age group Must already be on ICS to qualify |
Advair Diskus — COPD
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| COPD with exacerbation history (airflow obstruction maintenance) | 250/50 mcg 1 inh BID | 250/50 mcg BID | 250/50 mcg BID | Only approved COPD dose; 500/50 did not show additional benefit over 250/50 Higher pneumonia risk in COPD vs asthma |
Advair HFA (MDI) — Asthma Only
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Persistent asthma — based on severity (≥12 y) | 2 inh of 45/21, 115/21, or 230/21 mcg BID | 2 inh BID of selected strength | 2 inh of 230/21 mcg BID | Select strength by current ICS dose/severity Prime with 4 sprays before first use; re-prime if dropped or unused ≥4 weeks |
More than 1 inhalation of Advair Diskus twice daily is not recommended because patients are more likely to experience adverse effects from higher salmeterol doses. If response is inadequate, the correct approach is to step up to the next strength rather than increase the number of inhalations. Patients should never use a separate LABA in addition to Advair.
Pharmacology
Mechanism of Action
Fluticasone propionate (ICS component): A synthetic trifluorinated corticosteroid with high glucocorticoid receptor affinity and potent anti-inflammatory activity. After binding to intracellular receptors, fluticasone modulates gene transcription to suppress multiple inflammatory mediators (cytokines, leukotrienes, prostaglandins) and reduce inflammatory cell recruitment in the airways. This decreases bronchial hyperresponsiveness and controls the underlying inflammatory process driving persistent asthma and some features of COPD.
Salmeterol (LABA component): A selective, long-acting beta2-adrenergic agonist that relaxes bronchial smooth muscle by stimulating intracellular adenylyl cyclase, increasing cyclic AMP, and reducing intracellular calcium. The long lipophilic side chain of salmeterol anchors it near the beta2-receptor, providing sustained bronchodilation for approximately 12 hours per dose. The combination of an ICS plus a LABA provides complementary mechanisms — anti-inflammatory control plus bronchodilation — that together achieve better asthma control than increasing the ICS dose alone.
ADME Profile
| Parameter | Fluticasone Propionate | Salmeterol |
|---|---|---|
| Absorption | Oral bioavailability <1% (extensive first-pass); absolute bioavailability via Diskus ~13%; acts primarily locally in the lung | Low systemic bioavailability; acts locally on airway smooth muscle; onset of bronchodilation ~10–20 min |
| Distribution | Vd: 4.2 L/kg; protein binding: 91% | Protein binding: 96%; extensively distributed into tissues |
| Metabolism | Hepatic via CYP3A4 to inactive 17β-carboxylic acid metabolite | Hepatic via CYP3A4 to hydroxylated metabolites (alpha-hydroxysalmeterol); xinafoate salt moiety has no pharmacological activity |
| Elimination | t½: ~7.8 h; clearance ~1,093 mL/min; excreted primarily in feces (as metabolites) and <5% in urine | t½: ~5.5 h; eliminated in feces and urine |
Side Effects
Asthma (FDA PI Table 2 — Adults/Adolescents ≥12 y)
| Adverse Effect | Incidence (100/50 | 250/50) | Clinical Note |
|---|---|---|
| Upper respiratory tract infection | 27% | 21% | Placebo 14%; most commonly reported adverse event across all ICS/LABA trials |
| Pharyngitis | 13% | 10% | Placebo 6%; related to local steroid deposition; mouth rinsing may reduce |
| Headaches | 12% | 13% | Placebo 7%; may be partly salmeterol-related |
| Adverse Effect | Incidence (100/50 | 250/50) | Clinical Note |
|---|---|---|
| Upper respiratory inflammation | 7% | 6% | Placebo 5% |
| Bronchitis | 2% | 8% | Higher at 250/50; placebo 2% |
| Cough | 3% | 6% | Placebo 2%; may be paradoxical or related to powder inhalation |
| Nausea/vomiting | 4% | 6% | Placebo 1% |
| Hoarseness/dysphonia | 5% | 2% | Placebo <1%; local ICS effect; rinse mouth after use |
| Sinusitis | 4% | 5% | Placebo 4% |
| Oral candidiasis | 1% | 4% | Placebo 0%; dose-related; mouth rinsing is critical prevention |
| Viral respiratory infections | 4% | 4% | Placebo 3% |
| Musculoskeletal pain | 4% | 2% | Placebo 3% |
COPD-Specific Adverse Effects (FDA PI Table 3 — Diskus 250/50)
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Headaches | 16% | Placebo 12% |
| Candidiasis mouth/throat | 10% | Placebo 1%; substantially higher than in asthma trials; emphasize mouth rinsing |
| Adverse Effect | Estimated Frequency | Typical Onset | Required Action |
|---|---|---|---|
| Pneumonia (COPD) | 7% (1-yr 250/50); 16% (3-yr 500/50) vs 9% placebo | Ongoing risk; higher in patients >65 y (9–18%) | Remain vigilant for pneumonia symptoms overlapping with exacerbation; chest imaging if uncertain; consider ICS step-down |
| Adrenal suppression / HPA dysfunction | Rare at recommended doses | Weeks to months | Gradual dose reduction; cortisol assessment during steroid taper or stress |
| Anaphylaxis / severe hypersensitivity (milk protein allergy) | Very rare (postmarketing) | Minutes after dose | Emergency treatment; contraindicated in severe milk protein allergy (Diskus contains lactose) |
| Paradoxical bronchospasm | Rare | Immediately after inhalation | Rescue bronchodilator; discontinue Advair; alternative therapy |
| Cardiovascular effects (tachycardia, arrhythmias, QTc prolongation) | Uncommon at recommended doses; dose-related for salmeterol | Variable | ECG monitoring if symptoms; use with caution in cardiovascular disease; do not exceed recommended dose |
| Reduced bone mineral density | 3-yr COPD trial: fracture probability 6.3% Advair vs 5.1% placebo | Years | DEXA scan in at-risk patients; calcium/vitamin D supplementation |
| Growth suppression (pediatric) | ~1 cm/year reduction (ICS class effect) | First year | Regular stadiometry; titrate to lowest effective dose |
Pneumonia is a significant concern with ICS-containing inhalers in COPD patients. In the 3-year TORCH trial, pneumonia incidence was 16% with Advair 500/50 vs 9% with placebo, with even higher rates in patients over 65 years (18% vs 10%). Clinicians should weigh the exacerbation-reduction benefit against pneumonia risk, particularly in older patients. Clinical features of pneumonia and COPD exacerbation frequently overlap — obtain chest radiography when there is diagnostic uncertainty.
Drug Interactions
Both fluticasone propionate and salmeterol are substrates of CYP3A4. No formal drug interaction studies have been performed with the combination product, but the individual component interactions are well characterized. The most clinically significant concern is concurrent use of potent CYP3A4 inhibitors, which can increase systemic exposure to both components.
Monitoring
- Lung FunctionBaseline; 2 weeks; then q3–12 months
RoutineFEV1 and PEF confirm response. Improvement may begin within 30 minutes of the first dose. Reassess after 2 weeks; step up if inadequate. - Oropharyngeal ExamEach visit
RoutineCandidiasis incidence 1–10% in asthma trials, up to 10% in COPD. Reinforce mouth rinsing after every dose. - Pneumonia (COPD)Ongoing vigilance
Routine7–16% in COPD trials; obtain chest X-ray if exacerbation symptoms are atypical, include fever/consolidation, or fail to respond to bronchodilators. - Growth (Pediatric)Every 3–6 months
RoutineICS class effect: ~1 cm/year growth velocity reduction. Titrate to lowest effective dose. - Bone DensityBaseline (COPD); per risk factors
Trigger-basedFracture probability 6.3% vs 5.1% placebo in 3-year COPD trial. DEXA scan recommended in COPD patients at initiation and periodically. - OphthalmologyAnnually for long-term users
RoutineGlaucoma and cataracts reported with long-term ICS use. New glaucoma: 2% Advair vs 2% placebo in COPD subset. - Potassium / GlucoseIf concurrent diuretics or diabetes
Trigger-basedBeta2-agonists can cause transient hypokalemia and hyperglycemia. Clinically significant changes were infrequent in trials. - Adrenal FunctionDuring steroid taper; if Cushingoid features
Trigger-basedAM cortisol or cosyntropin stimulation test when transferring from oral steroids or using high-dose ICS long-term.
Contraindications & Cautions
Absolute Contraindications
- Status asthmaticus or acute episodes of asthma/COPD requiring intensive measures
- Severe hypersensitivity to milk proteins — Advair Diskus contains lactose monohydrate with trace milk proteins; postmarketing anaphylaxis reports
- Known hypersensitivity to fluticasone propionate, salmeterol, or any excipient
Relative Contraindications (Specialist Input Recommended)
- Active or quiescent pulmonary tuberculosis
- Untreated systemic fungal, bacterial, viral, or parasitic infections
- Ocular herpes simplex
Use with Caution
- Cardiovascular disorders — coronary insufficiency, arrhythmias, hypertension; salmeterol can produce clinically significant cardiovascular stimulation
- Convulsive disorders, thyrotoxicosis — sympathomimetic amine effects
- Diabetes mellitus — beta2-agonists may aggravate hyperglycemia
- Hepatic impairment — both components cleared hepatically; monitor for increased systemic exposure
- Concurrent strong CYP3A4 inhibitors — use not recommended per FDA PI
- Do not combine with other LABA-containing products
Long-acting beta2-adrenergic agonists (LABAs) such as salmeterol increase the risk of asthma-related death when used without an ICS. In the SMART trial, salmeterol monotherapy was associated with 13 asthma-related deaths per 13,176 subjects (vs 3 per 13,179 on placebo; RR 4.37). When LABAs are used in fixed-dose combination with ICS (as in Advair), large clinical safety trials (including a meta-analysis of 3 trials, n=35,089) did not show a significant increase in serious asthma-related events compared with ICS alone (HR 1.10 [95% CI: 0.85, 1.44]). Nevertheless, Advair should only be used in patients whose asthma is not adequately controlled on ICS or whose disease severity warrants dual therapy.
Deaths due to adrenal insufficiency have occurred in asthmatic patients during and after transfer from systemic corticosteroids to inhaled corticosteroids. Taper prednisone by 2.5 mg/day on a weekly basis. Patients previously on ≥20 mg/day prednisone are most susceptible. Carry a medical warning card.
Patient Counselling
Purpose of Therapy
Advair contains two medicines working together: one reduces airway inflammation (fluticasone, a steroid) and the other keeps airways open for 12 hours (salmeterol, a long-acting bronchodilator). Together they provide better asthma or COPD control than either medicine alone. Advair is a controller — it must be used every day to prevent symptoms and is not for sudden breathing problems.
How to Take
Use 1 inhalation (Diskus) or 2 inhalations (HFA) twice daily, approximately 12 hours apart. After every dose, rinse your mouth with water and spit it out. Discard the Diskus 1 month after opening the foil pouch or when the counter reads 0. Always carry a separate rescue inhaler. Never use more than prescribed, and do not use another LABA-containing product alongside Advair.
Sources
- Advair Diskus (fluticasone propionate and salmeterol inhalation powder) prescribing information. GlaxoSmithKline. Revised 03/2026. GSK Pro PI Primary source for all dosing, boxed warning text, adverse reaction Tables 2 and 3, PK data, and drug interaction guidance.
- Advair HFA (fluticasone propionate and salmeterol inhalation aerosol) prescribing information. GlaxoSmithKline. DailyMed Source for HFA-specific dosing (45/21, 115/21, 230/21 mcg) and HFA-specific adverse reaction data.
- Nelson HS, Chapman KR, Pyke SD, et al. Enhanced synergy between fluticasone propionate and salmeterol compared with individual components in the treatment of asthma. J Allergy Clin Immunol. 2003;112(1):29–36. DOI Pivotal trial demonstrating that ICS/LABA combination provides greater asthma control than either component alone.
- Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease (TORCH). N Engl J Med. 2007;356(8):775–789. DOI Landmark 3-year, 6,184-patient COPD trial; primary source for pneumonia incidence (16% Advair 500/50 vs 9% placebo) and fracture data.
- Stempel DA, Raphiou IH, Kral KM, et al. Serious asthma events with fluticasone plus salmeterol versus fluticasone alone (AUSTRI). N Engl J Med. 2016;374(19):1822–1830. DOI Post-SMART safety trial (n=11,679) demonstrating non-inferiority of ICS/LABA vs ICS alone for serious asthma events in adults/adolescents.
- Stempel DA, Szefler SJ, Pedersen S, et al. Safety of adding salmeterol to fluticasone propionate in children with asthma (VESTRI). N Engl J Med. 2016;375(9):840–849. DOI Pediatric safety trial (n=6,208, ages 4–11) demonstrating non-inferiority for serious asthma-related events (HR 1.29 [0.73, 2.27]).
- Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention. 2024 Update. GINA Reports Positions ICS/LABA at step 3 and above for persistent asthma management.
- Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for Prevention, Diagnosis and Management of COPD. 2024 Report. GOLD Reports COPD guideline positioning ICS/LABA for patients with exacerbation history and elevated eosinophil counts.
- Barnes PJ. Scientific rationale for inhaled combination therapy with long-acting beta2-agonists and corticosteroids. Eur Respir J. 2002;19(1):182–191. DOI Review of the synergistic molecular mechanisms underlying ICS/LABA combination therapy.
- Mackie AE, McDowall JE, Falcoz C, et al. Pharmacokinetics of fluticasone propionate inhaled via the Diskhaler and Diskus powder devices in healthy volunteers. Clin Pharmacokinet. 2000;39(Suppl 1):23–30. DOI Source for fluticasone propionate absolute bioavailability (~13% via Diskus), Vd (4.2 L/kg), and clearance data.
- Cazzola M, Page CP, Calzetta L, et al. Pharmacology and therapeutics of bronchodilators. Pharmacol Rev. 2012;64(3):450–504. DOI Comprehensive pharmacology review covering salmeterol PK, receptor binding kinetics, and duration of action.
- Nelson HS, Weiss ST, Bleecker ER, Yancey SW, Dorinsky PM; SMART Study Group. The Salmeterol Multicenter Asthma Research Trial. Chest. 2006;129(1):15–26. DOI Full publication of the SMART trial underlying the FDA boxed warning; documents salmeterol monotherapy risk (RR 4.37 for asthma-related death).